Medtronic R&D Spending Shifts To Neuromodulation, Diabetes

Medtronic is allocating an increasing share of R&D resources to its high-growth neuromodulation and diabetes care segments, at the expense of its larger but slower-growing cardiac rhythm disease management and cardiovascular care businesses